MariMed Inc. (OTCMKTS:MRMD – Get Free Report) was the target of a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 18,486 shares, a growth of 1,748.6% from the October 15th total of 1,000 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 761,607 shares, the days-to-cover ratio is presently 0.0 days.
MariMed Price Performance
Shares of MRMD traded up $0.00 during trading hours on Wednesday, reaching $0.07. 30,019 shares of the company’s stock traded hands, compared to its average volume of 581,557. The stock has a market cap of $29.82 million, a PE ratio of -1.85 and a beta of 1.54. The company has a current ratio of 0.92, a quick ratio of 0.34 and a debt-to-equity ratio of 1.78. The firm’s 50 day simple moving average is $0.07 and its 200-day simple moving average is $0.07. MariMed has a 12 month low of $0.04 and a 12 month high of $0.16.
MariMed (OTCMKTS:MRMD – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). MariMed had a negative net margin of 9.13% and a negative return on equity of 10.71%. The company had revenue of $41.92 million for the quarter, compared to analysts’ expectations of $39.80 million.
MariMed Company Profile
MariMed, Inc. is a U.S.-based cannabis company that develops, operates and manages licensed cannabis cultivation, processing and dispensary facilities. The company serves both medical and adult-use markets, where permitted by state law, and focuses on producing and distributing cannabis flower, concentrates, edibles, tinctures and other cannabis-infused products. MariMed markets products under brands that have included Betty’s Eddies, Nature’s Heritage, InHouse and Kalm Fusion. Its products are sold through the company’s retail operations and third-party dispensaries in its operating markets.
Recommended Stories
- Five stocks we like better than MariMed
- Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI Demand
- Alphabet Escalates AI Chip Rivalry With NVIDIA
- Amazon’s Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?
- 3 Stocks Wall Street Likes More Than the Market Does
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.
